Tags

Type your tag names separated by a space and hit enter

A molecular rationale for the how, when and why of colorectal cancer screening.
Aliment Pharmacol Ther 2001; 15(4):451-62AP

Abstract

Colorectal cancer remains a leading cause of cancer-related mortality in the United States. Recently, colorectal cancer screening and colorectal cancer prevention have gained national attention. In response, the American Gastroenterological Association, the American College of Gastroenterology and the Agency for Healthcare Policy and Research have published recommendations for colorectal cancer screening and surveillance in patients with sporadic as well as hereditary forms of colorectal cancer. This review will focus on the basic molecular differences underlying the formation of carcinoma in patients with sporadic colorectal cancer, and the heritable syndromes of familial adenomatous polyposis (FAP), hereditary non-polyposis colorectal cancer (HNPCC), and juvenile polyposis (JPS). By appreciating the molecular mechanisms underlying these four types of polyp cancer syndromes, the differences in clinical time course for progression from polyp to carcinoma and in current screening recommendations for patients with sporadic adenomas, FAP, HNPCC and JPS can be better understood.

Authors+Show Affiliations

Department of Medicine, Dallas VA Medical Center and University of Texas-Southwestern Medical Center at Dallas, TX, USA. rsouza@airmail.net

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

Language

eng

PubMed ID

11284773

Citation

Souza, R F.. "A Molecular Rationale for the How, when and Why of Colorectal Cancer Screening." Alimentary Pharmacology & Therapeutics, vol. 15, no. 4, 2001, pp. 451-62.
Souza RF. A molecular rationale for the how, when and why of colorectal cancer screening. Aliment Pharmacol Ther. 2001;15(4):451-62.
Souza, R. F. (2001). A molecular rationale for the how, when and why of colorectal cancer screening. Alimentary Pharmacology & Therapeutics, 15(4), pp. 451-62.
Souza RF. A Molecular Rationale for the How, when and Why of Colorectal Cancer Screening. Aliment Pharmacol Ther. 2001;15(4):451-62. PubMed PMID: 11284773.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A molecular rationale for the how, when and why of colorectal cancer screening. A1 - Souza,R F, PY - 2001/4/4/pubmed PY - 2001/5/22/medline PY - 2001/4/4/entrez SP - 451 EP - 62 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 15 IS - 4 N2 - Colorectal cancer remains a leading cause of cancer-related mortality in the United States. Recently, colorectal cancer screening and colorectal cancer prevention have gained national attention. In response, the American Gastroenterological Association, the American College of Gastroenterology and the Agency for Healthcare Policy and Research have published recommendations for colorectal cancer screening and surveillance in patients with sporadic as well as hereditary forms of colorectal cancer. This review will focus on the basic molecular differences underlying the formation of carcinoma in patients with sporadic colorectal cancer, and the heritable syndromes of familial adenomatous polyposis (FAP), hereditary non-polyposis colorectal cancer (HNPCC), and juvenile polyposis (JPS). By appreciating the molecular mechanisms underlying these four types of polyp cancer syndromes, the differences in clinical time course for progression from polyp to carcinoma and in current screening recommendations for patients with sporadic adenomas, FAP, HNPCC and JPS can be better understood. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/11284773/A_molecular_rationale_for_the_how_when_and_why_of_colorectal_cancer_screening_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=2001&volume=15&issue=4&spage=451 DB - PRIME DP - Unbound Medicine ER -